Topic Overview > The new GATA antibody

The new GATA antibody

A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)

Products

Products may not be approved or available in your region. Please check with your local Zytomed-Systems representative.
Product Clone Order no.
Host Rabbit
Clone ZR382
Format Concentrate
Reactivity -
Method P
Positive control Normal breast, breast carcinoma
Dilution 1:100 - 1:200
Isotype IgG
Immunogen Synthesized peptide corresponding to the C-terminus of human TRPS1 protein
Localization Nuclear
TRPS1 		ZR382 Z2673RL
Host Rabbit
Clone ZR382
Format Concentrate
Reactivity -
Method P
Positive control Normal breast, breast carcinoma
Dilution 1:100 - 1:200
Isotype IgG
Immunogen Synthesized peptide corresponding to the C-terminus of human TRPS1 protein
Localization Nuclear
TRPS1 		ZR382 Z2673RS
Host Rabbit
Clone ZR382
Format Concentrate
Reactivity -
Method P
Positive control Normal breast, breast carcinoma
Dilution 1:100 - 1:200
Isotype IgG
Immunogen Synthesized peptide corresponding to the C-terminus of human TRPS1 protein
Localization Nuclear
TRPS1 		ZR382 Z2673RT
Host Rabbit
Clone ZR382
Format r-t-u
Reactivity -
Method P
Positive control Normal breast, breast carcinoma
Dilution gebrauchsfertig
Isotype IgG
Immunogen Synthesized peptide corresponding to the C-terminus of human TRPS1 protein
Localization Nuclear
TRPS1 		ZR382 Z2673RP

Documents

New GATA Antibody

Download

Back to overview

Further topics

Product update: BRCA1 and BRCA2

The new AmoyDx® BRCA Pro Panel is an improved version of the AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit. Both kits enable analysis of the entire coding regions of the BRCA1 and BRCA2 genes, and of exon/ intron boundries in DNA from FFPE specimen and from peripheral whole blood.

Out Now: AmoyDx® FGFR1-4 NGS Panel

Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes

Products

Topics

Learning videos

Downloads

Company

Distributors

Privacy Imprint
DE EN